Get the Stockscreener App
0.848
2.42%
0.02
60 Degrees Pharmaceuticals Inc stock is traded at $0.848, with a volume of 115.17K.
It is up +2.42% in the last 24 hours and down -32.70% over the past month.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
See More
Previous Close:
$0.828
Open:
$0.829
24h Volume:
115.17K
Relative Volume:
0.22
Market Cap:
$1.95M
Revenue:
$502.40K
Net Income/Loss:
$-7.91M
P/E Ratio:
-0.085
EPS:
-9.972
Net Cash Flow:
$-4.32M
1W Performance:
-8.91%
1M Performance:
-32.70%
6M Performance:
-73.92%
1Y Performance:
-88.71%
1-Day Range:
$0.7904
$0.8499
1-Week Range:
$0.77
$0.9479
52-Week Range:
$0.7015
$10.67
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
Name
60 Degrees Pharmaceuticals Inc
Sector
Industry
Phone
202-327-5422
Address
1025 CONNECTICUT AVENUE NW, WASHINGTON
Compare SXTP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SXTP
60 Degrees Pharmaceuticals Inc
|
0.848 | 1.95M | 502.40K | -7.91M | -4.32M | -9.972 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
60 Degrees Pharmaceuticals Inc Stock (SXTP) Latest News
Palatin Technologies Inc (AMEX: PTN) Analysts Expect It Could Climb 93.76% From Current Levels. - Stocks Register
60 Degrees Pharmaceuticals Inc (NASDAQ: SXTP) Jumps 0.32 Percent In Recent Trading, What Questions Do You Have? – Stocks Register - Stocks Register
Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP) - Defense World
Titan Pharma (NASDAQ:TTNP) Stock Quotes, Forecast and News Summary - Benzinga
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates - MSN
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns Neutral Rating from HC Wainwright - Defense World
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $57.10 Consensus Target Price from Brokerages - Defense World
60 Degrees Pharmaceuticals Enrolls First Patient in Expanded Access Clinical Study for Babesiosis Treatment - Defense World
60 Degrees Pharmaceuticals enrolls first patient in tafenoquine study - Yahoo Finance
Barclays PLC Has $109,000 Stock Holdings in DLH Holdings Corp. (NASDAQ:DLHC) - Defense World
SXTP60 Degrees Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
60 Degrees Pharmaceuticals Enrolls First Patient in - GlobeNewswire
60 Degrees Pharma Launches Breakthrough Study for Stubborn Tick Disease Treatment After 80% Success - StockTitan
🚀 Wall Street Radar: Stocks to Watch Next Week - substack.com
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - News & Insights
Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy - Streetwise Reports
Maryland Biotech Gains Regulatory Approval - Streetwise Reports
Wainwright maintains neutral on SXTP stock after patent deal By Investing.com - Investing.com Australia
Wainwright maintains neutral on SXTP stock after patent deal - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
Sixty Degrees Pharmaceuticals and Tufts Medical Center - GlobeNewswire
60 Degrees Pharma Secures Exclusive Rights for Breakthrough Babesiosis Treatment with Tufts Medical Center - StockTitan
Insider Buying: Cheryl Xu Acquires 13,000 Shares of 60 Degrees P - GuruFocus.com
60 degrees pharmaceuticals director Cheryl Xu acquires $21,400 in stock - Investing.com India
60 degrees pharmaceuticals director Cheryl Xu acquires $21,400 in stock By Investing.com - Investing.com Australia
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns “Neutral” Rating from HC Wainwright - Defense World
60 Degrees Pharma shares stay Neutral amid progress on Arakoda trial - Investing.com
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital - The Manila Times
60 Degrees Pharmaceuticals launches babesiosis drug trial - Investing.com
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital - GlobeNewswire
60 Degrees Pharma Expands Promising Babesiosis Treatment Trial to Brigham & Women's Hospital - StockTitan
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: CMRX, CPIX, PCSA, CRDF, VRAR… - RTTNews
60 degrees pharmaceuticals CEO Geoffrey Dow acquires $89,755 in stock By Investing.com - Investing.com UK
60 degrees pharmaceuticals CEO Geoffrey Dow acquires $89,755 in stock - Investing.com
cbdMD (AMEX:YCBD) Stock Quotes, Forecast and News Summary - Benzinga
VSee Health CEO Reveals AI Platform's 1.5M Monthly Telehealth Encounters on Bloomberg TV | SXTP Stock News - StockTitan
VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
VSee Health CEO Reveals AI Platform's 1.5M Monthly Telehealth Encounters on Bloomberg TV | VSEE Stock News - StockTitan
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
60 Degrees & Can-Fite CEOs to Showcase Drug Pipeline on Bloomberg TV | SXTP Stock News - StockTitan
60 degrees pharmaceuticals CEO Geoffrey Dow acquires $6,367 in stock - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
60 Degrees Pharmaceuticals Reports 164% Sales Surge in Q3 2024, Driven by ARAKODA® Growth - GuruFocus.com
ARMISTICE CAPITAL, LLC Acquires New Stake in 60 Degrees Pharmace - GuruFocus.com
60 Degrees Pharmaceuticals Inc. Warrant (SXTPW) Quarterly 10-Q Report - Quartzy
HALO Stock Dips 5.77% Amid Biotech Sector Changes - GuruFocus.com
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results - Marketscreener.com
60 Degrees Pharma Reports 164% Revenue Surge, Doubles ARAKODA® Deliveries in Q3 | SXTP Stock News - StockTitan
OptiNose (OPTN) Reports Break-Even Earnings for Q3 - Nasdaq
60 Degrees Pharmaceuticals Inc Stock (SXTP) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):